In Segment C, contributors will receive ABBV-744 and oral navitoclax. In Segment D, contributors will acquire ABBV-744 and ruxolitinib. Contributors will acquire treatment right up until sickness progression or the contributors are not able to tolerate the study drugs. There may be increased treatment load for members During this trial https://brd4-targeted-therapy-abb92467.newsbloger.com/32645192/what-does-new-advancements-in-brd4-inhibition-therapy-abbv-744-mean